Loading
Menu
Phone :
+1 (858) 366 - 8608
Address :
NovaRhythm Biosciences, Inc
9311 SE Maricamp Rd #1007
Ocala, FL 34472 USA
Email :
info@novarhythmbio.com

© 2026, NOVARHYTHM BIOSCIENCES.

Transforming Atrial
Fibrillation Therapy

Discover Work

About Us

NovaRhythm Biosciences is a cardiovascular therapeutics leader developing first-in-class treatments for cardiac arrhythmias. Using human-based evidence and targeted ion channel pharmacology, NovaRhythm is advancing its lead program, SAR-297871 – a breakthrough dual-action therapy designed to restore rhythm and rate for atrial fibrillation (AF) patients.

News

NovaRhythm Biosciences In-Licenses SAR-297871 From Sanofi to Advance Precision Atrial Fibrillation Therapy

OCALA, FL, USA — April 1st, 2026 — EINPresswire.com.    NovaRhythm Biosciences, a biotechnology company developing next-generation therapeutics for cardiac arrhythmias, today announced the successful in-licensing of SAR-297871, a highly selective TASK-1 potassium channel inhibitor originally developed by Sanofi for the treatment of Atrial Fibrillation (AF).

 
Learn More

NovaRhythm Biosciences is advancing SAR-297871, a highly selective TASK-1 channel inhibitor that will restore both atrial rhythm and rate, without ventricular arrhythmia risk.

The Unmet Need in Atrial Fibrillation

Atrial Fibrillation (AF) is recognized as a growing global epidemic driven by aging and lifestyle factors, with over 60 million individuals affected worldwide. Despite advancements in ablation, surgical and device-based treatments, current pharmacological options for AF remain inadequate. Existing anti-AF drugs often suffer from low efficacy and significant safety risks, specifically the danger of pro-arrhythmia caused by unintended effects on ventricular ion channels.

Learn More

The Solution: One Molecule. Total Control. The Future of Atrial Fibrillation Therapy

SAR-297871 is an orally available, small-molecule inhibitor of the TASK-1 (K2P3.1) potassium channel, originally developed by Sanofi for the treatment of atrial fibrillation (AF). Extensive preclinical research and human cardiac tissue data support its potent, atrial-focused activity and differentiated safety profile.

NovaRhythm has licensed SAR-297871 from Sanofi and now holds exclusive global rights to advance the program through IND-enabling studies, clinical development and commercialization.

Learn More

NovaRhythm Biosciences will advance SAR-297871, a highly selective TASK-1 inhibitor that will restore both rhythm and rate, without ventricular arrhythmia risk.

The Unmet Need in Atrial Fibrillation

Atrial Fibrillation (AF) is the most common clinically significant arrhythmia, affecting over 59 million patients worldwide. Despite advances in ablation, devices, and anticoagulation, pharmacologic rhythm and rate control remains limited by modest efficacy and safety concerns. Many currently available anti-arrhythmic drugs also affect ventricular ion channels, increasing the risk of proarrhythmia and other adverse effects.

NovaRhythm Biosciences was founded to address this gap by developing atrial-specific therapeutics that restore and maintain sinus rhythm and rate while minimizing off-target cardiac risk.

Learn More

The Solution :  SAR 297871, a Selective TASK-1 Inhibitor

Atrial fibrillation (AF) is fundamentally a disease of abnormal atrial repolarization, driven by pathological shortening of atrial refractoriness. TASK-1, a potassium channel which is pathologically increased in AF, is the dominant atrial potassium leak channel responsible for remodeling of the atria—making it one of the most precise and atrial-selective therapeutic targets in modern electrophysiology.

NovaRhythm Biosciences was founded to address this gap by developing atrial-specific therapeutics that restore and maintain sinus rhythm and rate while minimizing off-target cardiac risk.

Learn More

Partnership

Partner & Investor Engagement

NovaRhythm Biosciences is driving the SAR-297871 program through IND and Phase 1 studies and is seeking engagement from investors and industry partners.

Learn More
Screenshot 2026-03-31 at 10.12.23 PM

J. Kevin Buchi

BOARD MEMBER AND M&A ADVISOR

Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. From 1991 to 2010, Mr. Buchi served as the Chief Financial Officer at Cephalon Pharmaceuticals and from 2010 to 2011 became the Chief Executive Officer to complete the $2 Billion acquisition of Cephalon by Teva Pharmaceutical. Subsequently, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd from 2012 to 2013. Mr. Buchi is currently on the Board of Directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) and of Benitec Biopharma (NASDAQ:BNTC). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.

Paul E. Miller, Ph.D.

BOARD MEMBER, CEO & FOUNDING PARTNER

Dr. Miller is the Founder and CEO of Consulting Life Sciences, a biotech consulting and brokerage firm he launched in 2007. From 2009 to 2023, he served as Co-Founder and Chief Corporate Development Officer of AnaBios Corporation, a company focused on advancing translational science through the use of primary human tissues in preclinical research. With over 40 years of experience in both science and business, Dr. Miller’s research background spans a wide range of fields, including cancer biology, immunology, protein secretion, gastrointestinal function, genomics, cardiology, pain and itch therapeutics. He also spent 20 years in the cultural arts industry before fully integrating his scientific knowledge with his business expertise in the biopharmaceutical sector. Throughout his career, Dr. Miller has led the development and commercialization of innovative services for preclinical contract research organizations (CROs), helping streamline drug discovery and safety testing—efforts that generated over $80 million in revenues.

Najah Abi Georges, Ph.D.

BOARD MEMBER, CSO & FOUNDING PARTNER

Dr. Abi Gerges has over 30 years of experience in cardiovascular research and 26 years in preclinical R&D. He is a seasoned leader in drug discovery. He spent 16 years at AstraZeneca and 10 years at AnaBios, where he currently serves as Senior Vice President of Research Alliances. Dr. Abi-Georges has authored more than 59 peer-reviewed publications and has been instrumental in developing several first-in-class therapies, including Tagrisso, Zeposia, Velsipity, and APD418. Known for his deep expertise in cardiovascular drug development and safety, he is widely respected across the pharmaceutical industry and regulatory agencies.

Cooley M. Pantazis, M.D.

BOARD MEMBER, CMO & FOUNDING PARTNER

Dr. Pantazis is a board-certified pathologist and has served as the Medical Director of Laboratory Services at Advent Health in Ocala, Florida, since 2015. Formerly, he was a tenured Associate Professor and Director of Surgical Pathology at the University of Kansas Medical Center. In 2005, he founded Hemacon Laboratories, a molecular hematopathology reference lab focused on diagnosing bone marrow and blood cancers. With over 40 years of experience in both medical practice and research, Dr. Pantazis has authored more than 75 peer-reviewed publications. His expertise includes animal cancer models, laboratory test development, and molecular cancer diagnostics, and he remains actively involved in research collaborations.

J. Kevin Buchi

M&A ADVISOR

Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. From 1991 to 2010, Mr. Buchi served as the Chief Financial Officer at Cephalon Pharmaceuticals and from 2010 to 2011 became the Chief Executive Officer to complete the $2 Billion acquisition of Cephalon by Teva Pharmaceutical. Subsequently, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd from 2012 to 2013. Mr. Buchi is currently on the Board of Directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) and of Benitec Biopharma (NASDAQ:BNTC). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.

Shashank Upadhye, J.D. LLM

IP ADVISOR

Mr. Upadhye is a partner at Upadhye Tang LLP and a nationally recognized pharmaceutical IP and FDA strategist with nearly 30 years of experience helping pharmaceutical companies maximize asset value and investor returns through integrated patent and regulatory planning. He previously served as Chief Legal/IP/FDA Counsel at Apotex, Sandoz/Novartis, and Eon Labs, where he guided numerous drug products from development through approval and commercialization, bringing deep operational and executive-level insight. Shashank specializes in designing robust patent portfolios, exclusivity strategies, and FDA regulatory pathways that enhance competitive positioning, extend franchise life, and unlock long-term enterprise value. He is the author of the leading treatise Generic Pharmaceutical Patent and FDA Law and is widely recognized as a trusted advisor to pharmaceutical companies, executives, and investors on high-stakes IP and regulatory strategy.

Peter R. Kowey, M.D.

FDA & REGULATORY ADVISOR

Dr. Kowey is a leading American cardiologist and medical researcher. He serves as Professor of Medicine and Clinical Pharmacology at Jefferson Medical College of Thomas Jefferson University and holds the William Wikoff Smith Chair in Cardiovascular Research at the Lankenau Institute for Medical Research. A recognized expert in cardiac rhythm disorders, Dr. Kowey has authored or co-authored over 400 scientific papers and received more than 150 research grants. He has played key roles in numerous clinical trials and co-edited three major textbooks on cardiac arrhythmias. Dr.Kowey is a fellow of multiple prestigious organizations, including the American Heart Association and the American College of Cardiology. He also serves on the editorial boards of Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology, and reviews manuscripts for 25 scientific journals. He has consulted for over 60 international pharmaceutical companies, chaired multiple data and safety monitoring boards, and served as an advisor to the U.S. Food and Drug Administration.

Cooley M. Pantazis, M.D.

CHIEF MEDICAL OFFICER & FOUNDING PARTNER

Dr. Pantazis is a board-certified pathologist and has served as the Medical Director of Laboratory Services at Advent Health in Ocala, Florida, since 2015. Formerly, he was a tenured Associate Professor and Director of Surgical Pathology at the University of Kansas Medical Center. In 2005, he founded Hemacon Laboratories, a molecular hematopathology reference lab focused on diagnosing bone marrow and blood cancers. With over 40 years of experience in both medical practice and research, Dr. Pantazis has authored more than 75 peer-reviewed publications. His expertise includes animal cancer models, laboratory test development, and molecular cancer diagnostics, and he remains actively involved in research collaborations.

Najah Abi Georges, Ph.D.

CHIEF SCIENTIFIC OFFICER & FOUNDING PARTNER

Dr. Abi Gerges has over 30 years of experience in cardiovascular research and 26 years in preclinical R&D. He is a seasoned leader in drug discovery. He spent 16 years at AstraZeneca and 10 years at AnaBios, where he currently serves as Senior Vice President of Research Alliances. Dr. Abi-Georges has authored more than 59 peer-reviewed publications and has been instrumental in developing several first-in-class therapies, including Tagrisso, Zeposia, Velsipity, and APD418. Known for his deep expertise in cardiovascular drug development and safety, he is widely respected across the pharmaceutical industry and regulatory agencies.

Paul E. Miller, Ph.D.

CHIEF EXECUTIVE OFFICER & FOUNDING PARTNER

Dr. Miller is the Founder and CEO of Consulting Life Sciences, a biotech consulting and brokerage firm he launched in 2007. From 2009 to 2023, he served as Co-Founder and Chief Corporate Development Officer of AnaBios Corporation, a company focused on advancing translational science through the use of primary human tissues in preclinical research. With over 40 years of experience in both science and business, Dr. Miller’s research background spans a wide range of fields, including cancer biology, immunology, protein secretion, gastrointestinal function, genomics, cardiology, pain and itch therapeutics. He also spent 20 years in the cultural arts industry before fully integrating his scientific knowledge with his business expertise in the biopharmaceutical sector. Throughout his career, Dr. Miller has led the development and commercialization of innovative services for preclinical contract research organizations (CROs), helping streamline drug discovery and safety testing—efforts that generated over $80 million in revenues.